In an effort to develop new targets for antibacterial drug discovery, we recently discovered that Gram positive bacteria use a unique and essential pathway to synthesize their membrane phospholipids mediated by two gene products, PlsX and PlsY. This pathway generates a unique acyl-phosphate intermediate via PlsX that is then utilized as a substrate for PlsY. PlsY is an essential acyltransferase and there are no mammalian homologs. Using a bioisosteric approach we designed a number of nonhydrolyzable mimics of the acyl-phosphate intermediate. When tested against a panel of representative gram positive pathogens these compounds showed only modest antimicrobial activity, with the exception of B. anthracis (Sterne strain) that was potently inhibited. To confirm this result we then tested these compounds against a panel of virulent B. anthracis strains, all of which were highly sensitive to our best inhibitors yielding comparable MIC activity to existing antibiotics. We believe that this is an ideal starting point for the development of selective B. anthracis inhibitors, which will be explored in this grant. This study has 3 specific aims: (i) To synthesize an expanded set of inhibitors and to optimize the lead compounds with respect to anti-anthracis activity and for potential oral bioavailability;(ii) to biochemically evaluate the inhibition of the B. anthracis PlsY enzymes by the newly synthesized inhibitors;(iii) To perform a microbiological assessment on the emerging lead compounds, including testing for anti-B. anthracis activity. The end point of our studies will produce a better understanding of this important biological pathway and determine whether it is a suitable target for antibacterial drug discovery.

Public Health Relevance

We propose to develop a novel class of antibiotics that selectively target bacillus anthracis phospholipid biosynthesis. These inhibitors will have the potential to be used for post exposure prophylaxis with minimal side effects.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
1R01AI079653-01A1
Application #
7627869
Study Section
Special Emphasis Panel (ZRG1-IDM-R (02))
Program Officer
Breen, Joseph J
Project Start
2009-08-19
Project End
2011-07-31
Budget Start
2009-08-19
Budget End
2010-07-31
Support Year
1
Fiscal Year
2009
Total Cost
$544,103
Indirect Cost
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Zheng, Zhong; Parsons, Joshua B; Tangallapally, Rajendra et al. (2014) Discovery of novel bacterial elongation condensing enzyme inhibitors by virtual screening. Bioorg Med Chem Lett 24:2585-8
Cherian, Philip T; Yao, Jiangwei; Leonardi, Roberta et al. (2012) Acyl-sulfamates target the essential glycerol-phosphate acyltransferase (PlsY) in Gram-positive bacteria. Bioorg Med Chem 20:4985-94
Hurdle, Julian G; O'Neill, Alex J; Chopra, Ian et al. (2011) Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections. Nat Rev Microbiol 9:62-75